Skip to contentV
Vaxcyte, Inc.
V
PCVXVaxcyte, Inc. PCVX Q3 2020 · Vaxcyte, Inc. · ThalerReleased Nov 12, 2020, after the close
10-Q filed Nov 12, 2020, 43 days after period end · 0001564590-20-053540
Q3 2020 · 10-Q
Revenue—
Net Income-$21.02M-$21.02MN/M vs Q3 2019N/M vs Q2 2020 EPS Diluted-$0.41-$0.41
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vaxcyte, Inc. · CIK 1649094 · Engraved from SEC EDGAR
N/M vs Q2 2020
Operating Income-$21,308,000N/M Operating Cash Flowderived-$13,055,000N/M Free Cash Flowderived-$13,084,000N/M ended Sep 30, 2020 · filed Nov 12, 2020 · 43 d after period end
+4.1% from the close of Nov 9, 2020 to the close of Nov 13, 2020, the first after the release.
after the close$36.50$38.00 Sep 25Nov 12Jan 12